Pangaea’s Co-founder and CTO, Professor Yike Guo, Awarded Wu Wen Jun AI Outstanding Contribution Award￼
London, UK, 11 May 2023: Pangaea Data (Pangaea) today announced that its co-founder and Chief Technology Officer (CTO), Professor Yike Guo, has been honored with the prestigious Wu Wen Jun AI Outstanding Contribution Award for their exceptional contributions in the field of Artificial Intelligence (AI). Professor Guo is a world-renowned expert in the field of AI and computer science.
Pangaea provides a novel Artificial Intelligence (AI)-driven product for characterizing patients by automatically discovering their clinical signatures (which clinicians currently manually ascertain) for 4,000 hard-to-diagnose conditions in a non-preemptive, evolving, privacy-preserving and scalable manner across 140,000 healthcare providers and pharmaceutical companies globally.
The Wu Wen Jun AI Science & Technology Award, which is initiated and hosted by the Chinese Association for Artificial Intelligence (CAAI), is known as the “highest award for AI science and technology in China”. It is given to individuals who have made significant contributions to the field of AI, with a particular emphasis on those whose work has had a profound impact on the development of AI.
“I am deeply honored to receive the Wu Wen Jun AI Outstanding Contribution Award,” said Professor Yike Guo. “It is a testament to the hard work and dedication of my team and collaborators. I believe that our work and application of AI to automatically characterize patients has the potential to transform the life sciences and healthcare industry and improve the lives of patients.”
The award ceremony was held on May 8, 2023, in Beijing, China. The award was presented by the Wu Wen Jun AI Science and Technology Foundation.
About Pangaea: www.pangaeadata.ai
Pangaea Data is a South San Francisco and London based provider of a novel AI-driven product to characterize patients by automatically discovering their clinical signatures across 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and scalable manner, which has clinically proven to discover 22x more undiagnosed, misdiagnosed and miscoded patients; match 5x more suitable clinical trials to patients; discover new insights across rare and hard-to-diagnose conditions; halve treatment costs; save 90% in operational costs and time; and drive sustainable collaborations between the healthcare and the pharmaceutical industry. The founders (Dr. Vibhor Gupta and Prof. Yike Guo) have attracted more than $200 million through their research and the company is advised by Lord David Prior (former Chairman of NHS England and Vice Chairman of Lazards), Mr. Andy Palmer (former Head of Systems Integration at Novartis and a prolific serial entrepreneur) and has published its work in high-impact, peer-reviewed journals and at conferences.